Printer Friendly

AFFYMAX N.V. ANNOUNCES RESEARCH COLLABORATION WITH SANDOZ PHARMA LTD.

AFFYMAX N.V. ANNOUNCES RESEARCH COLLABORATION WITH SANDOZ PHARMA LTD.
 AMSTERDAM, The Netherlands, Jan. 13 /PRNewswire/ -- Affymax N.V. (NASDAQ: AFMXF) announced today that it has entered into a research and development collaboration with Sandoz Pharma Ltd. under which Sandoz will fund Affymax research on the feasibility of developing a catalytic antibody which would be used in the manufacture of a Sandoz proprietary pharmaceutical.
 Under the agreement, Sandoz will fund three years of research at Affymax and have an option for certain exclusive rights to the results. In addition to the research and development funding, Affymax will receive milestone payments upon successful completion of feasibility work, as well as royalties on sales of any products manufactured using technology developed under this agreement.
 Affymax, a Netherlands corporation headquartered in Amsterdam, is developing new technologies to accelerate the pace of drug discovery and has additional research programs in diagnostic products and chemical process technology. Affymax is applying these technologies across a broad range of diseases to discover and develop products independently and in collaboration with established pharmaceutical companies. The majority of the company's research and development activities are performed by its wholly owned subsidiary, Affymax Research Institute, located in Palo Alto, Calif.
 Sandoz Pharma Ltd. ranks among the 10 leading companies in the pharmaceutical industry. Its products are used in the areas of organ rejection after transplantation, of endocrinological, immunological, cardiovascular and central-nervous-system disturbances, as well as asthma, allergies and pain.
 -0- 1/13/92 R
 /CONTACT: David B. Singer of Affymax, 415-496-2300/
 (AFMXF) CO: Affymax N.V. ST: California IN: MTC SU:


CH -- LA010 -- 8984 01/13/92 10:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1992
Words:270
Previous Article:CHICAGO TRIBUNE PRESENTS 'A VIEW OF CHICAGO FASHION' TODAY AT THE ST. REGIS ROOF
Next Article:SUPER BOWL XXVI ADVERTISING FALLS SHORT OF THE GOAL LINE
Topics:


Related Articles
AFFYMAX N.V. ANNOUNCES RESEARCH COLLABORATION WITH SANDOZ PHARMA LTD.
MARION MERRELL DOW COMMITS TO MAJOR EXPANSION OF AFFYMAX ALLIANCE
IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH
AFFYMAX AND ALZA SIGN DEFINITIVE AGREEMENT FOR JOINT DEVELOPMENT PROGRAM
SYSTEMIX AND SANDOZ PHARMA TO SCREEN AND TEST THERAPEUTIC AGENTS FOR HIV INFECTION
AFFYMAX N.V. ANNOUNCES STRATEGIC ALLIANCE WITH AMERICAN HOME PRODUCTS
CIBA AND AFFYMAX EXTEND RESEARCH COLLABORATION
CIBA AND AFFYMAX EXTEND RESEARCH COLLABORATION
PHARMACOPEIA AND SANDOZ PHARMA ANNOUNCE A RESEARCH AND DEVELOPMENT COLLABORATION
TRIPOS SOFTWARE ADOPTED BY SANDOZ PHARMA LTD. AT KEY RESEARCH SITES WORLDWIDE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters